<DOC>
	<DOCNO>NCT02158416</DOCNO>
	<brief_summary>The plan minimal risk study blind study consecutive transfusable platelet product . The aim study evaluate quality platelet component sample prior transfusion . The primary patient transfusion outcome study 1-hour correct count increment ( 1 hr CCI ) , widely accept clinical outcome measure . Platelet product sample ThromboLUX test send blood bank treatment center . After receipt treatment center , platelet product use per regular clinical practice , outcome data patient collect . At end study , TLX Scores compare transfusion outcome determine low TLX Score associate poor transfusion outcome . During course study , TLX Score known clinician , utilized way decide platelet product transfuse .</brief_summary>
	<brief_title>Platelet Products Tested With ThromboLUXÂ® Platelet Quality Test</brief_title>
	<detailed_description />
	<criteria>adult hematologyoncology outpatient stable thrombocytopenic age &lt; 18 yr splenomegaly unable provide inform consent pregnancy acute promyelocytic leukemia ITP ( Idiopathic thrombocytopenic purpura ) HUS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>platelet</keyword>
	<keyword>transfusion</keyword>
	<keyword>ThromboLUX</keyword>
	<keyword>correct count increment</keyword>
	<keyword>thrombocytopenic</keyword>
</DOC>